BioSpace News Archive

Azurity Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) approval of ZONISADE™.

Apyx Medical Corporation Receives FDA 510(k) Clearance for the Use of Renuvion ® to Improve Appearance of Lax (Loose) Skin.

PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that it has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside the US and Canada) to evaluate PC14586.

Prometheus Biosciences, Inc. today announced the completion of enrollment for Cohort 1 of the ARTEMIS-UC global Phase 2 study of PRA023 in ulcerative colitis (UC).

Eledon Pharmaceuticals, Inc. today reported that the first patient has been dosed in a Phase 1b study to evaluate tegoprubart in patients undergoing kidney transplantation.

SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that Laura Francis, CEO, and Anshul Maheshwari, CFO will be presenting at the upcoming Canaccord Genuity 42nd Annual Growth Conference in Boston.

HTG Molecular Diagnostics, Inc. announced it has entered into an amendment of its June 24, 2020 Loan and Security Agreement with Silicon Valley Bank, the bank of the world’s most innovative companies and investors.

Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that it participated in the National Institute of Health (NIH) funded Innovation Corps (I-Corps ™ ) program to accelerate commercialization of Daxor’s clinical decision support software.

China Pharma Holdings, Inc. (NYSE American: CPHI) (“China Pharma,” the “Company” or “We”), a specialty pharmaceutical company, today announced that on July 15, 2022 , the Company submitted a plan of compliance to NYSE American LLC (“NYSE American” or the “Exchange”) to address the deficiency in the Company’s stockholders’ equity as pointed out in the letter from the Exchange dated June 15, 2022 (the “Letter”).

Mindbloom, the leading provider of at-home ketamine therapy, announced Monday the findings of the largest-ever peer-reviewed clinical study of ketamine therapy.